default author photo

Shrina Patel

University of Texas at Houston - MD Anderson Cancer Center

Unit 1905

Houston, TX

United States

  • University of Texas at Houston - MD Anderson Cancer Center

SCHOLARLY PAPERS

1

DOWNLOADS

48

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Oral cyclophosphamide combined with bevacizumab in recurrent heavily pretreated ovarian cancer

Number of pages: 22 Posted: 06 Nov 2025
Mostafa F. Eyada, Victoria Michael, Shrina Patel, Jeffrey Andrew How, Roni Nitecki Wilke, Amir A. Jazaeri, Nicole D. Fleming, Pamela Soliman, Anil Sood, Shannon N. Westin and Travis T. Sims
affiliation not provided to SSRN, McGovern Medical School at UTHealth, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, affiliation not provided to SSRN, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine and affiliation not provided to SSRN
Downloads 48 (1,170,409)

Abstract:

Loading...

Recurrent ovarian cancer, High-grade serous ovarian cancer (HGSOC), Platinum resistant ovarian cancer (PROC), Cyclophosphamide, Bevacizumab.